AbbVie Reports $13.3 Billion in Q1 2025 Revenues, Acquires Nimble Therapeutics

AbbVie Inc. reported a financial performance for the first quarter of 2025, with net revenues reaching $13.3 billion, an increase of 8% from $12.3 billion in the same period of 2024. The company's operating earnings rose significantly to $3.7 billion, compared to $2.8 billion a year earlier. However, net earnings attributable to AbbVie Inc. decreased to $1.3 billion, or $0.72 per diluted share, down from $1.4 billion, or $0.77 per diluted share, in the prior year. The decline in net earnings was attributed to increased costs, including $1.9 billion related to the amortization of intangible assets and $1.5 billion for changes in the fair value of contingent consideration liabilities.

In terms of operational developments, AbbVie completed the acquisition of Nimble Therapeutics, Inc. for $288 million in January 2025, enhancing its capabilities in oral peptide therapeutics. The company also reported a significant increase in revenues from its immunology products, with Skyrizi and Rinvoq generating $3.4 billion and $1.7 billion, respectively, reflecting strong market uptake. Conversely, Humira's revenues fell sharply by 50% to $744 million, primarily due to the impact of biosimilar competition following the loss of exclusivity.

AbbVie’s total assets increased slightly to $136.2 billion as of March 31, 2025, from $135.2 billion at the end of 2024. The company’s cash and equivalents decreased to $5.2 billion, down from $5.5 billion, while accounts receivable rose to $12.5 billion, indicating a growing customer base. The company’s employee headcount remained stable at approximately 55,000. AbbVie also reported a gross margin of 70% for the quarter, up from 67% in the previous year, attributed to improved product mix and revenue growth.

Looking ahead, AbbVie anticipates continued growth driven by its diverse product portfolio and ongoing investments in research and development. The company plans to focus on maximizing the benefits of its acquisitions and expanding its pipeline, which currently includes around 90 compounds in development. AbbVie expects several regulatory submissions and data readouts from key clinical trials in the next 12 months, positioning itself for potential future growth despite challenges posed by global macroeconomic conditions and competitive pressures in the pharmaceutical industry.